Antibiotics Raw Material Powder CAS 96036-03-2 Meropenem

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Meropenem
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Solid
• Purity: >96%
• Name: Meropenem
• Mf: C17h25n3o5s
• CAS: 96036-03-2
• Transport Package: Drum
• Specification: 99%
• Trademark: HS
• Origin: China
• HS Code: 2904201000
• Production Capacity: 100000

Product Description

Product Name	Meropenem
Brand Name	HNB Biotech
Purity	99%
Molecular Formula	C17H25N3O5S
Appearance	White Powder
Test Method	HPLC

Meropenem, sold under the brandname Merrem among others, is a broad-spectrum antibiotic
used to treat a variety of bacterial infections.Some of these include meningitis, intra-abdominal
infection, pneumonia, sepsis, and anthrax. It is given by injection into a vein.

Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the
site of injection. Serious side effects include Clostridium difficile infection, seizures, and
allergic reactions including anaphylaxis. Those who are allergic to other β-lactam antibiotics
are more likely to be allergic to meropenem as well. Use in pregnancy appears to be safe. It
is in the carbapenem family of medications. Meropenem usually results in bacterial death
through blocking their ability to make a cell wall. It is more resistant to breakdown by
β-lactamase producing bacteria.

Meropenem was patented in 1983. It was approved for medical use in the United States in
1996. It is on the World Health Organization's List of Essential Medicines. The World Health
Organization classifies meropenem as critically important for human medicine.
Meropenem is administered intravenously as a white crystalline powder to be dissolved in 5%
monobasic potassium phosphate solution. Dosing must be adjusted for altered kidney function
and for haemofiltration.

As with other ß-lactams antibiotics, the effectiveness of treatment depends on the amount of
time during the dosing interval that the meropenem concentration is above the minimum
inhibitory concentration for the bacteria causing the infection. For ß-lactams, including
meropenem, prolonged intravenous administration is associated with lower mortality than
bolus intravenous infusion in persons with whose infections are severe, or caused by bacteria
that are less sensitive to meropenem, such as Pseudomonas aeruginosa.